Drugmaker follows Eli Lilly in cutting out middlemen and selling directly to patients
Tech companies have been wilfully ignoring the protection of the young for decades
. . . turn out to make a lot of sense
Agreement worth up to $1.2bn includes plan for combined flu and Covid shots
Experts are divided on whether the shift towards private care is good or bad for the public health service in the long term
Latest data from UK Health Security Agency shows jump in cases in first three months of the year
The technology can do wonderful things — but its achievements should not come at the expense of basic protections
Women’s rights campaigners optimistic parliament will support one of the amendments to criminal justice bill next week
Saving humanity’s a costly business
AlphaFold 3 aims to reveal biological secrets and boost drug search efforts
Anglo-Swedish drugmaker says availability of newer vaccines hit demand for jab
Army intervention part of mission to prevent spread of contagious African swine fever to pigs
Food and Drug Administration poised to call for outside assessment of Lykos PTSD therapy in test for psychedelics sector
Weight-loss treatments are not the only source of excitement in the pharmaceutical research world
Novo Nordisk, Bill & Melinda Gates Foundation and Wellcome focus on interlinked issues
Experts warn better data is required to drive policy as debilitating condition reduces workforce
IPPR researchers describe government’s laissez-faire approach to public health as a ‘failed experiment’
Employees are being offered the ‘party drug’ through company health schemes as psychedelic-assisted therapy grows in popularity
The curious case of the Hackney Mole Man
Boom in healthcare borrowing prompts warnings from doctors and campaigners
While pandemic risk is low, scientists say urgent investigations into the virus are necessary
Even in the most hostile environments, green spaces have long been a place to dream
An FT special report looking at changes in healthcare, treatments and illness itself
For stretched public health budgets, high-tech treatments are hard to afford but some pre-emptive measures can prove good value
Caseloads of cancer and other illnesses of ageing are forecast to rise steeply in lower income countries
UK Edition